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Abstract
Body clearance of fungi such as Candida albicans involves phagocytosis by fixed tissue 
macrophages as well as infiltrating monocytes and neutrophils. Through phagocyto-
sis, the fungi are confined and killed by the oxidative and non-oxidative anti-microbial 
systems. These include oxygen derived reactive species, generated from the activation 
of the NADPH oxidase complex and granule constituents. These same mechanisms 
are responsible for the damage to hyphal forms of C. albicans. Complement promotes 
phagocytosis, through their interaction with a series of complement receptors includ-
ing the recently described complement receptor immunoglobulin. However, it is also 
evident that under other conditions, the killing of yeast and hyphal forms can occur in 
a complement-independent manner. Phagocytosis and killing of Candida is enhanced 
by the cytokine network, such as tumour necrosis factor and interferon gamma. 
Patients with primary immunodeficiency diseases who have phagocytic deficiencies, 
such as those with defects in the NADPH oxidase complex are predisposed to fun-
gal infections, providing evidence for the critical role of phagocytes in anti-fungal 
immunity. Secondary immunodeficiencies can arise as a result of treatment with anti-
cancer or other immunosuppressive drugs. These agents may also predispose patients 
to fungal infections due to their ability to compromise the anti-microbial activity of 
phagocytes.
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1. Introduction
C. albicans is considered to be the most common fungus causing both skin and disseminated 
disease, particularly in immunodeficient and immunocompromised patients. Phagocytes, 
particularly neutrophils, play an important role in clearing candidal infections. The impor-
tance of neutrophils in immunity to C. albicans is clearly evident from the increased rate of 
infection seen in patients with severe neutropenia [1].
In neutrophils, the major response associated with phagocytosis of microbial pathogens is 
the oxygen-dependent respiratory burst and the generation of reactive oxygen species (ROS). 
Several decades ago it became evident that neutrophils displayed a unique respiratory burst 
in the absence of mitochondria, where the generation of ATP comes mainly from glycolysis 
(reviewed in [2]). It also became apparent that the majority of the oxygen consumed was 
converted to superoxide (O·
2
–) which is then converted to further oxygen intermediates, 
including singlet oxygen and H
2
O
2
. The enzyme which catalyses the conversion of O
2
 to O·
2
– 
is assembled in the phagocytic vacuole membrane, facilitating its release into the bacteria 
or fungus-containing vacuole. In neutrophils, the release of the azurophilic granule content 
simultaneously into the phagocytic vacuole leads to the generation of HOCl, a highly potent 
anti-microbial agent, as a result of the action of myeloperoxidase on H
2
O
2
 in the presence 
of chloride ions. In addition, ingestion of microbial pathogens and their confinement to the 
vacuolar environment may restrict the supply of essential nutrients necessary for growth.
The NADPH oxidase complex is responsible for the respiratory burst and consists of a num-
ber of different proteins which assemble in the neutrophil vacuole membrane following cell 
stimulation. This is typically initiated during phagocytosis of bacteria and fungi [3]. The com-
plex consists of the oxidase-specific phox proteins gp91phox, p22phox, p40phox, p47phox, p67phox and 
the small GTPases, Rac1 and Rac2. Cell activation leads to the assembly of these components 
in the membrane and the initiation of enzymatic activity.
The non-oxidative microbicidal system complements the respiratory burst. Components of 
the azurophilic granules in neutrophils have been shown to have anti-microbial activity. 
These include defensins, serprocidins and bactericidal/permeability increasing protein (BPI). 
Defensins are cationic peptides with broad spectrum antimicrobial activity [2]. The seropro-
dins, elastase, azurocidin and cathepsin G have antimicrobial activity independent of their 
enzymatic activity [2].
As with neutrophils, most bacteria and fungi are confined and killed within phagosomes 
by macrophages [4], involving a variety of agents such as toxic metabolites, peptides and 
enzymes. These may act either alone or synergistically. In addition, macrophages can produce 
ROS which have anti-microbial action but unlike monocytes, macrophages lack MPO. Most 
striking is the marked heterogeneity of macrophages enabling these leukocytes to perform 
functions relevant to specific tissues in which they are located.
The extrusion of neutrophil extracellular traps (NETs) is also considered to be a defence 
mechanism against microbial pathogens. NETs are structures composed of DNA as well as 
anti-microbial substances, elastase, calprotectin and MPO [5]. NETs not only trap the micro-
bial pathogens, but also kill them. Interestingly, it has been reported that the formation of 
NETs requires the presence of ROS [6].
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Effective recognition of microbial pathogens by neutrophils and macrophages requires recep-
tors which bind peptides deposited on bacterial and fungal surfaces which have been gener-
ated through the activation of complement, namely C3b and iC3b. Receptors recognising iC3b 
include CR3 (CD18/CD11b) and CR4 (CD18/CD11c), which are present on both neutrophils 
and macrophages. Recently, another complement receptor type, complement immunoglobu-
lin receptor (CRIg), expressed only by a subpopulation of macrophages has been described, 
which binds both iC3b and C3b (reviewed in [7]). It has been shown that this receptor plays 
an important role in clearance of bacteria from the circulation by liver Kupffer cells [8] and 
may also be a pattern recognition receptor, facilitating clearance of bacteria in the absence of 
complement [9].
Antibody bound to microbial pathogens also promotes phagocytosis through the Fcγ recep-
tors, FcγRI (CD64), FcγRIIA (CD32) and FcγRIIIB (CD16), all of which engage the Fc domain of 
Immunoglobulin G (IgG). The FcαRI which binds the Fc domain of Immunoglobulin A (IgA) 
also promotes microbial phagocytosis and killing [2].
Apart from the integrins and FcγRs, neutrophils and macrophages express a range of pattern 
recognition receptors (PPR) which recognise conserved microbial pathogen structures, such 
as lipoteichoic acid, β-glucans and lipopolysaccharide. Families of PPRs include those found 
in serum (pentraxins, collectins, complement), those which are membrane bound (classic 
C-type lectins, non-classic C-type lectin leucine-rich proteins, scavenger receptors) and those 
which are located intracellularly (NODs, interferon induced proteins).
2. Complement dependent and independent phagocytosis of C. 
albicans
Despite the importance of complement-independent mechanisms for host anti-candidal 
immunity, it is evident that complement is required for optimal resistance to fungal infection 
[10–12]. It was also evident in these studies that complement could be activated by C. albicans 
by the alternative pathway. Activation of complement leads to the generation of chemotactic 
peptides and C5a, which attracts neutrophils to the site of candidal infection [13, 14]. Thong 
and Ferrante [11], in their studies on the generation of chemotaxis promoting factors by serum 
treated with C. albicans, showed that this activity was totally dependent on heat-labile fac-
tors and activation of complement via the alternative pathway. Chemotaxis of neutrophils 
towards fungus-treated serum was abolished when the serum was either heated at 56°C for 
20 min or was C2 deficient (where the alternative but not the classical pathway can be acti-
vated). The subsequent step, phagocytosis, was also highly dependent on heat labile opsonins 
[12]. However, while the chemotactic response was totally dependent on serum complement, 
the heat labile opsonins only acted to enhance other phagocytosis-promoting mechanisms. 
Thus, significant phagocytosis was still observed in the presence of heat-inactivated serum. 
In both of these studies on chemotaxis and phagocytosis-promoting activity of serum, it was 
shown that these principles applied to a wide-range of clinical isolates of C. albicans from 
patients and both including Serotypes A and B [11, 12].
Zymosan A is a yeast cell wall glucan and, like C. albicans derived β(1,3) (1,6)-glucan, is an ago-
nist to TLR2 and Dectin-1 [15]. Using commercially available labelled zymosan A bioparticles 
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which are non-fluorescent outside of the cell and fluoresce once taken into acidic phago-
somes, we showed that neutrophils require opsonising conditions to phagocytose particles 
efficiently (Figure 1). This supports the findings of [16], and demonstrates that like monocytes 
and macrophages, neutrophils require complement for the rapid phagocytosis of yeast par-
ticles. Interestingly, the complement dependency of phagocytosis diminished at incubation 
times of 45–60 min, where complement-independent mechanisms of phagocytosis become 
more prominent (Figure 1C).
The classical complement pathway is likely to be activated by mannan-specific antibod-
ies found in human serum [19] whereas the lectin pathway is activated by the binding of 
mannose-binding lectin to mannan on the cell wall of the fungus [20]. However, it has also 
been shown that C. albicans can bind the complement regulatory protein, C4b-binding protein 
(C4BP), thereby inactivating C4b and hence preventing complement activation on the yeast 
surface. As a result, the microbial pathogen will evade complement activation via the classical 
and lectin pathways, but the alternative pathway remains operative, generating chemotac-
tic factors and opsonins. Furthermore, C. albicans has the ability to regulate the alternative 
pathway and factors H and FHL-1 [21]. The binding of these regulators is seen with both the 
cellular and hyphal forms of C. albicans [22].
The unique complement receptor CRIg is a member of the transmembrane protein of the 
type 1 immunoglobulin superfamily, encoded by VSIG4. Although two spliced forms of CRIg 
have been described, a long (L) and short (S) form [8], we have recently identified five forms 
based on expression of transcripts and western blot analysis [23]. The receptor is expressed 
selectively by a subpopulation of macrophages, probably of the M2 type, and is abundant 
in fixed tissue macrophages such as liver Kupffer cells and resident peritoneal macrophages 
[24, 25]. Unlike CR3 and CR4 which require prior activation, CRIg is naturally active and its 
activity is controlled by its recycling pattern from the endoplasmic reticulum [8]. Our studies 
have demonstrated that cytokines alter CRIg expression in human macrophages and this was 
associated with a corresponding change in ability of neutrophils to phagocytose C. albicans in 
a complement-dependent manner [23, 26, 27].
While CR3 and FcRγ mediate phagocytosis of complement and antibody opsonised C. albi-
cans, in the absence of these opsonins, adherence and phagocytosis by neutrophils and mac-
rophages is promoted by C-Type Lectin Receptors (CLRs), in particular Dectin-1 [28–31]. The 
targets for Dectin-1 are β-1,3 glucan polymers, major components of the fungal cell wall. In 
C. albicans hyphae, this polymer is masked and appears to be different in the yeast form [32].
Cells of the phagocytic system are able to recognise C. albicans through multiple classes of 
receptors [33]. These include pattern recognition receptors (PRRs) such as Toll-like receptor 
(TLRs) 4 and 2 [34, 35], and CLRs such as Dectin-1 and the mannose receptor [36]. While 
these receptors are able to induce phagocytosis independently of complement, efficiency of 
uptake in both macrophages and neutrophils can be significantly increased when C. albicans 
is opsonised [16]. Under these conditions CR3 present on phagocytes is able to recognise 
iC3b deposited on the fungal cell surface and promote phagocytosis. In macrophages, this 
process is also able to occur through CRIg [27]. Agents such as dexamethasone that promote 
the upregulation of CRIg protein expression are also able to induce increased levels of phago-
cytosis of C albicans [23], suggesting that CRIg rather than CR3 plays an important role in the 
phagocytosis of C. albicans in macrophages.
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Neutrophils recognise C. albicans through the PRRs TLR2, TLR4 and Dectin-1, and also under 
opsonising conditions through FcγR and CR3 [37]. Similar to macrophage phagocytosis of 
C. albicans, uptake of isolated fungal zymosan A is more efficient in opsonising conditions, 
with phagocytosis after a 15-min incubation time being three times higher in reactions with 
complement compared to no serum and heat-inactivated serum controls (Figure 1).
Figure 1. Complement-dependent and -independent phagocytosis of zymosan A bioparticles by human neutrophils. (A) 
Phagocytosis of C. albicans under the different treatment conditions indicated in the x-axis. Results are the mean ± SD 
of three experiments. (B) Representative histogram/gating strategy for these experimental runs. In these experiments 
the reaction was terminated at 30 min. Neutrophils only are shown by the dashed line, no serum in black, heat-
inactivated serum shown in blue, and native AB serum shown in red. (C) Phagocytosis kinetics over a 60 min incubation 
period in the presence or absence of serum. Results are presented as mean ± SD of triplicate reactions. Neutrophils 
were prepared from human peripheral blood from healthy volunteers, using the high density gradient method [17]. 
Phagocytosis was assayed using pHrodo™Red Zymosan A bioparticles (ThermoFisher, Walter MA, Cat no. P35364) 
as described previously [18]. Human AB serum was prepared from peripheral blood of healthy volunteers. The serum 
was shown to have normal levels of complement activity using the CH50 assay. AB serum heated at 56°C for 20 min 
was confirmed to lack complement activity. The cell samples were analysed using a FACSCanto I flow cytometer (BD). 
The work was approved by the Human Research Ethics Committee of the Women’s and Children’s Hospital Network, 
Adelaide. Statistical analyses were carried out by ANOVA followed by Dunnet’s post hoc test. (D) Photomicrographs of 
the interaction of C. albicans with neutrophils in the presence or absence of serum at a 1:1 and 1:4 neutrophil:fungal ratio. 
Red arrows indicate phagocytic vacuoles following the digestion of the yeast or non-degraded yeast particles (following 
30 min of incubation).
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C. albicans is able to exist in multiple forms, as a single-celled budding yeast or in pseudohy-
phal or hyphal filamentous forms [38]. While in its unicellular form, the fungus can be toler-
ated as a commensal organism by the oral or vaginal epithelium. However, when it converts 
to its hyphal form, the fungus displays pathogenic properties. The host is able to discriminate 
against the potential danger [37] through MAPK-based recognition in the epithelial cells [39], 
which leads to mitogen-activated protein kinase phosphatase 1 (MKP1) and c-Fos activation. 
Neutrophils also play a role in this protection through TLR4-mediated recognition [40].
3. Trained macrophage immunity in anti-fungal immunity
Trained immunity (TI) refers to the ability of innate immune cells to exhibit ‘memory’ and 
prevent reinfection of previously encountered invading pathogens [41]. Termed by Netea 
and colleagues [42], TI induces a state of enhanced antimicrobial action in cells of the innate 
immune system, particularly monocytes and macrophages, which is distinct from both typi-
cal innate immunity and the memory of the adaptive immune system. Alternatively, TI refers 
to the enhanced response to reinfection against the initial invading microorganisms and 
cross-protection against different pathogens. Although the concept of TI is relatively new, the 
phenomenon of protection afforded by previous infection in a manner distinct from adaptive 
immunity has long been known, particularly in plant and insect systems [43, 44].
TI has been shown to have a role in infection and immunity against C albicans. Bistoni et al. 
[45] demonstrated that not only did injection with a non-pathogenic strain of C. albicans 
induce protection against reinfection, but also cross-protected against the other pathogens 
Candida tropicalis and Staphylococcus aureus. This protection was determined to be macro-
phage-dependent, as transfer of adherent splenic cells from mice administered with the non-
pathogenic strain conferred protection to the recipient mice. Two decades later, Quintin et al. 
[46] expanded on this concept, demonstrating that mice injected with low doses of C. albicans 
showed increased survival rates when administered lethal infection loads, and increased 
proinflammatory cytokine production upon secondary exposure. This protection was also 
shown in mice deficient in T and B cells and not in mice lacking CCR2, indicating that similar 
to the results of Bistoni et al. [45], the observed protection was monocyte-dependent. It was 
also shown that training of monocytes could be induced through purified β-glucan, a poly-
saccharide that makes up the cell wall of selected bacteria and fungi [47]. The group further 
investigated the mechanisms behind this protection by analysis of the genome-wide binding 
pattern of the methylation marks on histone 3 lysine 4 (H3K4me3) and on histone 3 lysine 27 
(H3K27me3), and concluded that protection was controlled at the epigenetic level through 
H3K4me3 in known genes involved in innate immunity. Furthermore, mRNA levels of TNF 
and IL-6 were higher in trained monocytes compared with non-trained control cells.
While other molecules such as fungal chitin have also been shown to induce TI [48], β-glucan 
remains the most well-studied molecule with respect to C. albicans, which has been shown to 
induce TI in both human and murine systems [46, 49, 50]. Along with its antimicrobial prim-
ing, β-glucan-induced TI has also been investigated in anti-tumour immunity [51].
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4. Killing of C. albicans by neutrophils and macrophages
Ferrante [52] demonstrated that killing of yeast forms of C. albicans and Candida glabrata was 
associated with release of the ROS, superoxide, and constituents of azurophilic granules and 
specific granules. During this interaction the generation of HOCl occurred, another potent 
anti-fungal agent. The importance of ROS was demonstrated by the finding that inhibitors 
of superoxide and H
2
O
2
 decreased intracellular killing of C. albicans [53]. Further proof of the 
role of ROS generation in the killing of C. albicans came from the demonstration that neutro-
phils and macrophages from patients with chronic granulomatous disease (CGD) (who have 
defective NADPH oxidase activity), were unable to effectively kill the fungi [54]. However, 
whether ROS per se are responsible for the killing of C. albicans remains to be established [55]. 
The reaction of H
2
O
2
 with MPO, in the presence of chloride ions, forms a very potent anti-
microbial system. We have previously demonstrated that opsonised C. albicans induces the 
release of both H
2
O
2
 and MPO, thereby establishing an anti-candidal environment [52]. The 
importance of MPO in the killing of C. albicans is supported by the finding that neutrophils 
and monocytes from MPO deficient patients failed to kill C. albicans [56, 57].
In vivo the absence of MPO in macrophages may be overcome by the cells incorporating MPO 
released by neutrophils at infection sites. Thus, resident peritoneal mouse macrophages in 
the presence of recombinant MPO caused an increase in intracellular killing of C. albicans [58]. 
However, it is noteworthy that using mouse models of X-linked CGD and MPO deficiency, 
susceptibility was most evident in the former, suggesting that ROS are the major mediators 
of candidicidal activity [59]. In comparison, the neutrophil-mediated damage to C. albicans 
pseudohyphae was found to be mediated by the oxidative burst and MPO [60]. Interestingly, 
this neutrophil-mediated damage occurred in the absence of serum complement.
Two distinct mechanisms for human neutrophil-mediated killing have been documented, 
depending on the state of fungal opsonisation. Using in vitro fungicidal assays, Gazendam 
et al. [61] showed that killing of un-opsonised C. albicans was dependent on CR3 and phos-
phatidylinositol-3-kinase (PI3K) signalling, but was independent of NADPH oxidase activa-
tion. However, the killing of antibody opsonised C. albicans by neutrophils was dependent on 
Fcγ receptors and protein kinase C (PKC) in addition to NADPH.
5. Intracellular signalling required for killing of C. albicans
Approximately two decades ago it was demonstrated that human neutrophil-mediated killing 
of C. albicans, in a complement-dependent manner, required the activation of the extracellular 
signal-regulated protein kinase cascade [62]. More recently it has been reported that PKCδ 
activation downstream of the receptors Dectin-1 and Mac-1 is important in the neutrophil-
mediated resistance to C. albicans and fungi-induced ROS generation [63]. In contrast, while 
PKCδ deficiency in macrophages prevented the stimulation of production of ROS induced by 
C. albicans, this did not affect the killing of the fungus. It has been demonstrated that BTK and 
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Vav1 are Dectin-1 interacting proteins [64]. These were found to be recruited to phagocytic 
cups containing yeast or hyphae of C. albicans, at the less mature stage of phagosome develop-
ment. These contribute to the Dectin-1 dependent phagocytosis of C. albicans.
In comparison, Gazendam et al. [61] demonstrated that neutrophils display two different 
mechanisms in the killing of C. albicans by evaluating patients with Dectin-1 deficiency, 
CARD9 deficiency or NADPH deficiency. One of these mechanisms was CR3, PI3K and 
CARD9 dependent, but independent of ROS generation. The other was selectively dependent 
on Fcγ, PKC and ROS generation. Both of these candidicidal pathways required Syk tyrosine 
activation but were independent of Dectin-1.
6. Neutrophil extracellular traps in immunity to C. albicans
C. albicans has been shown to induce NET extrusion in phagocytes, particularly in neutro-
phils. While the formation of this structure is considered as part of cell death or NETosis [65], 
Byrd et al. [66] reported that the rapid extrusion of NETs in response to C. albicans occurs 
in the absence of cell death. However, others have demonstrated that the yeast forms of C. 
albicans stimulated NETs through autophagy and ROS generation in the early stage of the 
interaction (first 15 min) [67]. However, with the hyphal forms, NET formation occurred via 
autophagy and not ROS generation. In the longer term (4 h), only the hyphae stimulated 
NETs. Interestingly, they found less killing of yeast forms by NETs compared to the high 
level of damage to the hyphae forms. Other strategic functions of extracellular protrusions of 
neutrophils have been demonstrated for Plasmodium falciparum. Here, the neutrophils were 
observed to ‘throw out’ protrusions which penetrated the parasitophorous vacuole contain-
ing the intraerythrocytic stage of the parasite and withdrawing the parasite without damag-
ing the erythrocyte [68].
7. Cytokine priming in phagocyte-mediated killing of C. albicans
Over three decades ago it became evident that neutrophil responses to microbial pathogens 
could be significantly increased if the cells were pre-sensitised with products released by 
activated lymphocytes and macrophages [69], a process dependent on the presence of TNF 
[70, 71]. The importance of cytokine priming in killing of C. albicans by neutrophils was also 
observed [72]. Thus, neutrophil mediated killing of C. albicans and a related fungus, Candida 
glabrata was significantly increased if the phagocytes had been pre-treated with either TNF 
or GM-CSF [52, 73]. The TNF treatment also increased the candida-induced release of ROS 
and MPO, consistent with the increased anti-fungal activity induced by the cytokines [52]. 
The mechanism by which TNF primes neutrophils for increased killing of C. albicans has not 
been studied. However, these mechanisms can be inferred from studies with other micro-
bial pathogens. Kowanko et al. [74] demonstrated that the TNF-induced effects responsible 
for increased microbial killing could be mediated by both oxygen-dependent and oxygen- 
independent mechanisms, with respect to killing of opsonised S. aureus and Plasmodium falci-
parum infected erythrocytes, respectively. Furthermore, studies with the pathogenic soil amoeba, 
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N. fowleri have shown that the TNF-enhanced killing requires a functional H
2
O
2
-MPO-halide 
system [75]. The priming of neutrophils by TNF is reflected by an increase in expression of 
CR3 and CR4 on the surface of these cells. The enhanced killing of S. aureus was dependent 
on these receptors, given that this was not seen upon the addition of anti-CD11b and -CD11c 
monoclonal antibodies [76].
The use of TNF to enhance immunity against various microbial infections has not been con-
sidered appropriate because of the highly toxic and tissue damaging effects of TNF. In an 
effort to harness the anti-infective properties of TNF and exclude some of its tissue damaging 
properties, we synthesised short peptides representative of the TNF sequence [77]. One of 
these elevenmer peptides, TNF70–80, was found to activate neutrophils and macrophages to increase microbial killing both in vitro and in vivo [77–81].
Our studies with C. albicans demonstrated that TNF70–80 also protected against infections with this fungus (Tables 1 and 2). In the first set of experiments, the effect of administering either 
TNF or TNF70–80 to mice infected with C. albicans was examined. The recovery of fungi from 
Treatment No. mice/group Log CFU/g kidney (M ± SD)
PBS 23 7.3 ± 0.6
Amphotericin B 15 2.7 ± 2.4***
TNF (0.1 mg/kg) 29 5.6 ± 1.2***
TNF70–90 (4 mg/kg) 9 5.75 ± 1.7**
Eight week old Balb/c mice were challenged with 5 × 105 CFU C. albicans intravenously. Treatment of mice commenced 
24 h prior to infection, and continued with daily administration until 2 days post-infection. Mice were sacrificed on day 
2 and kidney preparations plated on Sabouraud agar. The degree of infection was determined by enumeration of the 
number of organisms in the kidney at the time of euthanisation (**p < 0.01, ***p < 0.001, 1-way ANOVA, SNK test). The 
research received approval from the Women’s and Children’s Hospital Animal Ethics Committee.
Table 1. The effect of TNF and TNF70–80 on C. albicans infection in mice.
Treatment Route Dose (mg/kg) Survivors 10 days post-infection
Vehicle control IP — 8
Cyclophosphamide PO 30 2*
TNF70–80 + cyclophosphamide IP 100 7ns
TNF70–80 + cyclophosphamide IP 10 4ns
TNF70–80 + cyclophosphamide IP 1 4ns
TNF70–90 + cyclophosphamide IP 0.1 2*
Azimexone + cyclophosphamide IP 100 6ns
Balb/c mice (10/group) were treated with 3 doses of oral (OP) cyclophosphamide (30 mg/kg) and infected with C. 
albicans as described in Table 1. Mice were also treated with three doses of TNF70–80 at the schedule described in Table 1. Azimexone (used as a positive control) was administered intraperitoneally (IP) (n = 10 mice, *p < 0.05, ns: not significant, 
one-sided Fisher’s exact test). The research received approval from by Women’s and Children’s Hospital Animal Ethics 
Committee.
Table 2. Effect of TNF70–80 on C. albicans infection in immunocompromised mice.
The Role of Phagocytes in Immunity to Candida albicans
http://dx.doi.org/10.5772/intechopen.80683
103
the kidneys of these mice was significantly lower than in non-treated control mice (Table 1). 
In the second experimental set-up, mice treated with cyclophosphamide became highly sus-
ceptible to C. albicans with the survival of mice dropping from 80 to 20%, 10 days after infec-
tion. If the mice had been treated with TNF70–80, survival was increased with 70% survival observed at the highest dose (Table 2).
Cytokines also influence the ability of macrophages to phagocytose and kill fungi. Human 
monocyte-derived macrophages (MDMs) treated with interferon gamma showed increased 
ability to phagocytose and kill yeast forms of C. albicans [82]. The cytokine treated cells showed 
a corresponding increase in ROS production when challenged with the fungus. This effect of 
interferon gamma was evident with non-opsonised C. albicans and was independent of CR3. 
These effects of interferon gamma were reproduced with mouse peritoneal macrophages [83]. 
M-colony stimulating factor has also been shown to increase macrophage phagocytosis and 
killing of C. albicans yeast forms and cause damage to hyphae [84].
From the described studies, it is evident that when considering killing of microbial pathogens 
including C. albicans, this needs to be interpreted in terms of the cytokine milieu generated 
during the infection. It is evident from other published work that several cytokines regulate 
phagocyte-mediated microbial killing properties, including interferon gamma, lymphotoxin 
and interleukin-1 [71, 85].
8. Primary immunodeficiency diseases associated with susceptibility 
to fungal infection
Primary immunodeficiency diseases (PID) are a heterogeneous group of inborn errors of 
immunity. Affected individuals develop severe, unusual or recurrent infections, and may 
also develop features of immune dysregulation with autoimmune manifestations. There 
are currently over 320 described molecular genetic causes of PID, which can be categorised 
according to presenting phenotypic features [86]. The International Union of Immunological 
Sciences (IUIS) classify PID into the following disease categories: immunodeficiencies affect-
ing cellular and humoral immunity, combined immunodeficiencies (CID) with associated 
or syndromic features, predominantly antibody deficiencies, diseases of immune dysregu-
lation, congenital defects of phagocyte number, function or both, defects in intrinsic and 
innate immunity, auto-inflammatory disorders, complement deficiencies and phenocopies 
of PID [86].
Intact immunological processes and pathways are required to mount an effective immune 
response against fungi, incorporating both innate and adaptive components [87]. Several 
immune cells and immunological mediators such as cytokines are of critical importance to 
maintenance of anti-fungal immunity. These include phagocytes, dendritic cells, T cells (par-
ticularly T helper 1 (TH1) and T helper 17 (TH17) cells) [87]. The importance of these effec-
tors is evidenced by patients with PID affecting cellular or phagocytic immunity developing 
severe, invasive or recurrent fungal infections [1].
Primary phagocytic disorders result from mutations in genes encoding key proteins that are 
essential for normal phagocytic development and function. These disorders may be classified 
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according to whether phagocyte number, function or both are affected, and by the presence 
or absence of associated syndromic features [86]. These disorders and their underlying, caus-
ative genetic abnormality are summarised in Table 3.
Congenital defects of phagocytic number, function or both
Associated with syndromic features Not associated with syndromic features
Disorder Gene(s) Disorder Gene(s)
Shwachman-Diamond 
syndrome
SBDS, DNAJC21 Elastase deficiency (SCN1) ELANE
G6PC3 deficiency (SCN4) G6PC3 Kostmann disease (HAX1 deficiency; SCN3) HAX1
Glycogen storage disease 
type 1b
G6PT1 GFI1 deficiency (SCN2) GFI1
Cohen syndrome COH1 X-linked neutropaenia/myelodysplasia WAS 
GOF
WAS
Barth syndrome 
(3-methylglutaconic aciduria 
type II)
TAZ G-CSF receptor deficiency CSF3R
Clericuzio syndrome 
(poikiloderma with 
neutropaenia)
C16ORF57 (USB1) Neutropaenia with combined immune 
deficiency
MKL1
VPS45 deficiency (SCN5) VPS45
P14/LAMTOR2 deficiency LAMTOR2
JAGN1 deficiency JAGN1
3-methylglutaconic aciduria CLPB
SMARCD2 deficiency SMARCD2
WDR1 deficiency WDR1
HYOU1 deficiency HYOU1
Congenital defects of phagocytic function
Associated with syndromic features Not associated with syndromic features
Disorder Gene(s) Disorder Gene(s)
Cystic fibrosis CFTR Chronic granulomatous disease CYBB, NCF1, 
CYBA, NCF4, 
NCF2
Papillon-Lefevre syndrome CTSC Rac2 deficiency RAC2
Localised juvenile 
periodontitis
FPR1 G6PD deficiency Class 1 G6PD
Leukocyte adhesion 
deficiency (LAD) 1
ITGB2 GATA2 deficiency (MonoMac syndrome) GATA2
Leukocyte adhesion 
deficiency (LAD) 2
SLC35C1 Specific granule deficiency C/EBPE
Leukocyte adhesion 
deficiency (LAD) 3
FERMT3 Pulmonary alveolar proteinosis CSF2RA, CSF2RB
Adapted from [86].
SCN = severe congenital neutropaenia, WAS = Wiskott-Aldrich Syndrome, GOF = gain of function.
Table 3. Primary immunodeficiency diseases affecting phagocytic number and/or function.
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Of the described primary immunodeficiency diseases of phagocytic number or function, 
recurrent or invasive candidal disease has been reported in cases of chronic granuloma-
tous disease and myeloperoxidase deficiency [1] and GATA2 deficiency [88]. Candidosis is 
reported but tends to be less common in leukocyte adhesion deficiency and congenital neu-
tropaenic syndromes [1].
Chronic granulomatous disease (CGD) occurs as a result of defects in components of the 
NADPH oxidase system, resulting in defective neutrophil oxidative burst and susceptibility 
to a narrow range of organisms, particularly those which are catalase-producing. As well as 
the predisposition to infection, patients with CGD develop a hyperinflammatory response 
and granuloma formation [89]. X-linked CGD occurs due to mutations in the CYBB gene 
which encodes the NADPH oxidase complex component gp91phox [86]. Autosomal recessive 
forms of CGD are less common, and occur due to mutations in the NCF1, CYBA, NCF4 or 
NCF2 genes, which encode for other components of the complex, namely p47phox, p22phox, 
p40phox and p67phox, respectively [86, 89].
Candidosis is well described in CGD patients, with candidal species implicated in episodes of 
meningitis, fungaemia, suppurative adenitis, pneumonia, subcutaneous abscesses and liver 
abscess reported in a cohort of 368 patients with CGD [90]. Although the majority of these 
infections were expected to be due to underlying, impaired phagocytic function, additional 
factors such as steroid use likely increase the risk of invasive candidiasis. Candidal oesopha-
gitis, keratitis and disseminated infection (particularly affecting young infants) have also been 
described, however mucocutaneous candidiasis is uncommon in CGD patients [1].
Patients with gp40phox mutations have been noted to have a distinct clinical phenotype as com-
pared with those with other forms of CGD, with a milder clinical course and lower frequency 
of invasive fungal infection [91]. There is no impairment in the ability of the neutrophils of 
affected patients to kill candida, suggesting residual NADPH oxidase activity and a potential 
gp40phox-independent process for reactive oxygen species production. Furthermore, monocyte 
and monocyte-derived macrophage NADPH oxidase generation appears to occur indepen-
dently of gp40phox [91]. In patients with CGD, a correlation has been shown between residual 
production of reactive oxygen intermediates (ROI) and improved long-term survival [92]. The 
specific mutation in NADPH oxidase predicts the amount of residual production of ROI [92].
CGD may be conservatively managed with antibiotic and antifungal prophylaxis, along with 
adjunctive therapies including subcutaneous interferon therapy. CGD is curable by haemato-
poietic stem cell transplantation (HSCT), and trials are underway to evaluate the role of gene 
therapy as an alternative definitive management strategy [93].
MPO deficiency is autosomal recessive with variable penetrance, may be complete or partial, 
and has an estimated incidence of between 1:2000 and 1:4000 individuals [94]. Most individu-
als are clinically asymptomatic, although severe infections are reported in around 5% of those 
affected. MPO-deficient phagocytes have an impaired capacity to kill C. albicans, as evidenced 
by severe infection in MPO-deficient mice.
GATA2 encodes a zinc finger transcription factor which is critical for haematopoetic cell devel-
opment [95]. Mutations in this gene give rise to a syndrome also known as ‘MonoMac’, which 
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refers to the monocytopaenia and predisposition to mycobacterial infection which are char-
acteristic of this condition [95, 96]. In addition, affected patients have other haematological 
anomalies including thrombocytopaenia and neutropaenia, predisposition to haematologi-
cal malignancy and severe mycobacterial, fungal and human papilloma viral infections [88, 
96]. In a recent study of 79 French and Belgian patients with GATA2 mutations, 16 patients 
were reported to have had 18 episodes of fungal infection, 5 of which were candidoses [88]. 
Eight of the 18 infections were associated with chemotherapy or HSCT. The neutrophils from 
some GATA2 deficient patients were noted to have reduced granularity [97]. When stimu-
lated with PHA (phytohaemagglutinin), patient PBMCs (peripheral blood mononuclear cells) 
demonstrated reduced lymphocyte proliferative and cytokine production capacity, which 
normalised after addition of monocytes [96], highlighting the important role of these cells in 
eliciting an effective immune response.
In addition to the critical role of phagocytes in anti-fungal immunity, defects in other immune 
cells and immunologic pathways also give rise to susceptibility to infection with candida and 
other fungi. A range of single-gene inborn errors of immunity resulting in severe or recurrent 
superficial or invasive candidiasis have been described [86, 98]. Cell-mediated immunity is 
essential for anti-fungal immunity. This is evidenced by the predisposition to severe fungal 
infection in infants with severe combined immunodeficiency (SCID), a life-threatening condi-
tion manifested by low, absent or severely dysfunctional T cells [86]. Other forms of combined 
immunodeficiency, for example, those due to deficiencies in CD25, NEMO/IKBG, DOCK8, 
TCR-α, ORAI1, MST1/STK4, MHC Class II, along with IKBA gain of function mutations and 
idiopathic CD4+ T cell lymphopaenia are associated with chronic mucocutaneous candidiasis 
(CMC) [98]. In addition, CMC is a feature of several PID with syndromic features, includ-
ing STAT3 deficiency (autosomal dominant hyper-immunoglobulin E syndrome), APECED 
(autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia), also known as APS-1 
(autoimmune polyglandular syndrome type 1) which occurs due to mutations in the AIRE 
gene), and deficiencies of IL12Rβ, IL-12p40 and CARD9 [98, 99]. The importance of the TH17 
pathway and IL-17 signalling in anti-candidal immunity has become apparent [100, 101], with 
severe CMC described in patients with deficiencies of IL-17RA, IL-17F, RORC and STAT1 
gain of function mutations [98, 102]. In particular, AIRE has been demonstrated to have a key 
role in anti-candidal immunity, as evidenced by its role in fungal synapse formation which is 
required for initial macrophage recognition of fungal hyphae [103]. AIRE, along with Dectin-1, 
Dectin-2, Syk and CARD9 are required for formation of the fungal synapse upon stimulation 
of macrophage-like THP-1 cells after stimulation with C. albicans [103].
9. Secondary immunodeficiency diseases associated with disorders 
of phagocyte number or function
Immunosuppression is a well-described risk factor for infection with candida and other fungal 
species [98]. Corticosteroids are commonly used in the management of a range of inflamma-
tory and malignant conditions, and use of these agents is a known risk factor for fungal infec-
tion [104]. The precise mechanisms by which corticosteroids lead to impaired anti-candidal 
The Role of Phagocytes in Immunity to Candida albicans
http://dx.doi.org/10.5772/intechopen.80683
107
immunity remain unclear, and this is likely multifactorial [105]. In terms of phagocytic cell 
function, corticosteroids appear to alter leukocyte differentiation programs. They induce 
monocytes and macrophages to adopt an anti-inflammatory phenotype. This is modulated by 
the cytokine environment (including increased IL-10 expression on macrophages), increased 
apoptotic activity and induction of transcription of anti-inflammatory genes which impact 
upon chemotaxis, phagocytosis and resistance to oxidative stress [105]. However, despite 
these observations it has been recently shown that dexamethasone increases the expression 
of CRIg on human MDMs but not CR3 or CR4, and that this increase was associated with an 
increase in phagocytosis of complement opsonised C. albicans [23, 26, 27].
Cancer patients are at an increased risk of systemic candidiasis, and C. albicans is reported 
to be one of the most common causes of sepsis in this patient group [104]. This predisposi-
tion to fungal infection is multifactorial, and may be due to a secondary immunodeficiency 
caused by the underlying malignancy itself, or due to the effects of chemotherapeutic 
agents. Chemotherapeutic drugs may induce neutropaenia or affect neutrophil function, 
thereby impairing anti-candidal immunity. Neutrophil function may be impaired as a result 
of reduced trafficking, chemotaxis or phagocytic activity. For example, chemotherapeutics 
targeting microtubule structures likely impair cytoskeletal processes and actin polymerisa-
tion, thereby reducing neutrophil chemotaxis and phagocytosis. Chemotherapeutic agents 
can also interfere in NETosis, which is important for antimicrobial activity. Some drugs may 
also induce monocytopaenia and impaired monocytic function, further increasing the risk of 
candidal infection [104].
Patients with liver disease are at an increased risk of fungal infection. Those with cirrhosis 
have been found to have reduced complement levels and impaired monocyte activation and 
neutrophil mobilisation [106]. Patients with liver disease are at risk for infectious peritonitis, 
and C. albicans and C. neoformans were amongst the main species isolated in these cases. Renal 
disease is also a risk factor for invasive fungal disease [104]. Neonatal candidal sepsis has been 
reported in association with jaundice [107]. Interestingly, unconjugated bilirubin in hyperbili-
rubinemia has also been linked to reduced phagocytic cell function; phagocytosis and killing 
of fungi [108, 109]. Burns patients are at increased risk of fungal infection owing to a breached 
skin barrier and use of antimicrobial agents, with candidal infection in particular being asso-
ciated with increased morbidity and mortality in these patients [106]. In addition to these 
disease states, other physical factors, alone or in combination, such as the use of intravenous 
catheters and mechanical ventilation also increase the risk of invasive fungal disease [98, 104].
Finally, it is also evident that anti-fungal drugs per se can compromise immunity [109–111]. 
Several of the imidazoles were found to inhibit neutrophil functions, chemotaxis, phagocyto-
sis and microbial killing of bacteria and candida [110].
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